Finally, while computational drug discovery programs have been largely correlative1, we made use of recent causal structure discovery algorithms11,47,48 to validate the identified drug targets and their downstream effects, thereby identifying protein kinase inhibitors such as axitinib, dasatinib, pazopanib, and sunitinib as drugs of particular interest for the repurposing against COVID-19. Here, WEE1 is linked to COVID-19.